Pasireotide LAR

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Acromegaly

Conditions

Acromegaly, Pituitary Gigantism

Trial Timeline

Oct 16, 2012 → Apr 10, 2017

NCT ID

NCT01673646

About Pasireotide LAR

Pasireotide LAR is a phase 2 stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT01673646. Target conditions include Acromegaly, Pituitary Gigantism.

What happened to similar drugs?

13 of 20 similar drugs in Acromegaly were approved

Approved (13) Terminated (1) Active (7)

🔄Pasireotide LARNovartisPhase 3

🔄Octreotide acetate 30 mg suspensionNovartisPhase 3

✅Sandostatin LAR + pegvisomant + cabergolineNovartisApproved

✅Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved

✅Sandostatin LARNovartisApproved

🔄Pasireotide + OctreotideNovartisPhase 3

✅Sandostatin (Octreotide Acetate)NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02354508	Phase 3	Completed	Mar 31, 2015	Sep 27, 2018	Acromegaly
NCT01283542	Phase 2	Completed	Nov 26, 2012	Sep 12, 2017	Non-functioning Pituitary Adenoma
NCT01673646	Phase 2	Completed	Oct 16, 2012	Apr 10, 2017	Acromegaly
NCT01364415	Phase 1	Completed	Aug 1, 2011	Apr 1, 2016	Neuroendocrine Tumors
NCT00958841	Phase 2	Terminated	Sep 1, 2009	Jun 1, 2015	Pancreatic Neoplasm

Competing Products

20 competing products in Acromegaly

See all competitors

Product	Company	Stage	Hype Score
Alesse	Novartis	Phase 2	31
ONO-5788 + ONO-5788 Placebo + Octreotide	Ono Pharmaceutical	Phase 1	21
ONO-5788 + [14C]-ONO-5788	Ono Pharmaceutical	Phase 1	29
Pasireotide LAR	Novartis	Phase 3	40
Octreotide acetate 30 mg suspension	Novartis	Phase 3	40
Pasireotide long acting release formulation	Novartis	Pre-clinical	26
Sandostatin LAR + pegvisomant + cabergoline	Novartis	Approved	43
Octreotide acetate and cabergoline/Octrotide and Somavert	Novartis	Approved	43
Sandostatin LAR	Novartis	Approved	43
Pasireotide + Octreotide	Novartis	Phase 3	40
Sandostatin (Octreotide Acetate)	Novartis	Approved	39
Octreotide acetate	Novartis	Approved	35
octreotide FluidCrystal® injection depot	Novartis	Phase 2	35
Octreotide LAR	Novartis	Phase 3	40
Octreotide LAR	Novartis	Phase 3	40
Pasireotide	Novartis	Phase 2	35
Pasireotide LAR 60 mg + Pegvisomant	Novartis	Approved	39
Octreotide	Novartis	Approved	43
Octreotide LAR 30 MG Injection	Novartis	Approved	43
Pasireotide (SOM230), Octreotide (Sandostatin)	Novartis	Phase 2	35